{"organizations": [], "uuid": "39ac61718ddc0331b5fb33dd55b3072d13efbd2c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-zealand-announces-successful-end-o/brief-zealand-announces-successful-end-of-phase-2-meeting-with-fda-on-glepaglutide-for-short-bowel-syndrome-idUSASO0003UM", "country": "US", "domain_rank": 408, "title": "BRIEF-Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-26T07:57:00.000+03:00", "replies_count": 0, "uuid": "39ac61718ddc0331b5fb33dd55b3072d13efbd2c"}, "author": "", "url": "https://www.reuters.com/article/brief-zealand-announces-successful-end-o/brief-zealand-announces-successful-end-of-phase-2-meeting-with-fda-on-glepaglutide-for-short-bowel-syndrome-idUSASO0003UM", "ord_in_thread": 0, "title": "BRIEF-Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "zealand pharma a/s", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - Zealand Pharma A/S:\n* ZEALAND ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA ON GLEPAGLUTIDE FOR SHORT BOWEL SYNDROME\n* SAYS PIVOTAL PHASE 3 TRIAL IS ON TRACK FOR INITIATION IN Q3 2018\n* ZEALAND EXPECTS TO INITIATE PIVOTAL PHASE 3 TRIAL IN Q3 2018\n* SCIENTIFIC ADVICE WITH EUROPEAN MEDICINES AGENCY (EMA) IS ONGOING WITH AN EXPECTED OUTCOME BY MID-2018 Source text for Eikon:\n ", "external_links": [], "published": "2018-04-26T07:57:00.000+03:00", "crawled": "2018-04-26T08:21:45.004+03:00", "highlightTitle": ""}